You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFentanyl
Accession NumberDB00813  (APRD00347, DB05853)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational, Vet Approved
DescriptionA potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
Structure
Thumb
Synonyms
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
Fentanil
Fentanila
Fentanilo
Fentanyl
Fentanyl
Fentanyl CII
Fentanylum
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
Phentanyl
External Identifiers
  • AD 923
  • AD-923
  • IDS-NF-001
  • McN-JR 4263-49
  • R 4263
  • R 5240
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbstralTablet200 mcgSublingualPaladin Labs Inc2011-04-18Not applicableCanada
AbstralTablet100 ug/1SublingualPro Strakan, Inc.2011-01-07Not applicableUs
AbstralTablet400 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet800 mcgSublingualPaladin Labs Inc2011-06-03Not applicableCanada
AbstralTablet600 ug/1SublingualPro Strakan, Inc.2011-01-07Not applicableUs
AbstralTablet100 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet600 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet300 mcgSublingualPaladin Labs Inc2011-04-18Not applicableCanada
AbstralTablet200 ug/1SublingualPro Strakan, Inc.2011-01-07Not applicableUs
AbstralTablet800 ug/1SublingualPro Strakan, Inc.2011-01-07Not applicableUs
AbstralTablet200 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet800 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet400 mcgSublingualPaladin Labs Inc2011-04-18Not applicableCanada
AbstralTablet300 ug/1SublingualPro Strakan, Inc.2011-01-07Not applicableUs
AbstralTablet300 ug/1SublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
AbstralTablet100 mcgSublingualPaladin Labs Inc2011-04-18Not applicableCanada
AbstralTablet600 mcgSublingualPaladin Labs Inc2011-06-14Not applicableCanada
AbstralTablet400 ug/1SublingualPro Strakan, Inc.2011-01-07Not applicableUs
Abstral FentanylTablet, orally disintegrating200 ug/1SublingualSentynl Therapeutics, Inc.2016-10-01Not applicableUs
Abstral FentanylTablet, orally disintegrating800 ug/1SublingualSentynl Therapeutics, Inc.2016-10-01Not applicableUs
Abstral FentanylTablet, orally disintegrating300 ug/1SublingualSentynl Therapeutics, Inc.2016-10-01Not applicableUs
Abstral FentanylTablet, orally disintegrating400 ug/1SublingualSentynl Therapeutics, Inc.2016-10-01Not applicableUs
Abstral FentanylTablet, orally disintegrating600 ug/1SublingualSentynl Therapeutics, Inc.2016-10-01Not applicableUs
Abstral FentanylTablet, orally disintegrating100 ug/1SublingualSentynl Therapeutics, Inc.2016-10-01Not applicableUs
ActiqLozenge200 ug/1Oral; TransmucosalCephalon, Incorporated1998-11-04Not applicableUs
ActiqLozenge1200 ug/1Oral; TransmucosalCephalon, Incorporated1998-11-04Not applicableUs
ActiqLozenge400 ug/1Oral; TransmucosalCephalon, Incorporated1998-11-04Not applicableUs
ActiqLozenge1600 ug/1Oral; TransmucosalCephalon, Incorporated1998-11-04Not applicableUs
ActiqLozenge600 ug/1Oral; TransmucosalCephalon, Incorporated1998-11-04Not applicableUs
ActiqLozenge800 ug/1Oral; TransmucosalCephalon, Incorporated1998-11-04Not applicableUs
Co FentanylPatch50 mcgTransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co FentanylPatch75 mcgTransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co FentanylPatch100 mcgTransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co FentanylPatch12 mcgTransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co FentanylPatch37 mcgTransdermalCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co FentanylPatch25 mcgTransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
DuragesicPatch50 ug/hTransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
DuragesicPatch75 mcgTransdermalJanssen Inc2009-05-11Not applicableCanada
DuragesicPatch75 ug/hTransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
DuragesicPatch100 mcgTransdermalJanssen Inc2009-05-11Not applicableCanada
DuragesicPatch100 ug/hTransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
DuragesicPatch25 mcgTransdermalJanssen Inc2009-05-11Not applicableCanada
DuragesicPatch12.5 ug/hTransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
DuragesicPatch12 mcgTransdermalJanssen Inc2010-03-16Not applicableCanada
DuragesicPatch50 mcgTransdermalJanssen Inc2009-05-11Not applicableCanada
DuragesicPatch25 ug/hTransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
Duragesic 100Patch100 mcgTransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic 12Patch12 mcgTransdermalJanssen Inc2006-08-012009-11-24Canada
Duragesic 25Patch25 mcgTransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic 50Patch50 mcgTransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic 75Patch75 mcgTransdermalJanssen Inc1992-12-312009-11-24Canada
EffentoraTablet100 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet800 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet400 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet100 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet800 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet400 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet200 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet600 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet200 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
EffentoraTablet600 microgramsBuccalTeva B.V.2008-04-04Not applicableEu
FentanylPatch25 ug/hTransdermalSandoz,Inc.2004-10-01Not applicableUs
FentanylPatch50 ug/hTransdermalSandoz,Inc.2004-10-01Not applicableUs
FentanylPatch12 ug/1TransdermalDispensing Solutions, Inc.2004-10-01Not applicableUs
FentanylPatch75 ug/hTransdermalSandoz,Inc.2004-10-01Not applicableUs
FentanylPatch12.5 ug/hTransdermalSandoz,Inc.2004-10-01Not applicableUs
FentanylPatch100 ug/hTransdermalSandoz,Inc.2004-10-01Not applicableUs
FentanylPatch12.5 ug/hTransdermalbryant ranch prepack2004-10-01Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousHospira, Inc.1985-01-12Not applicableUs
Fentanyl CitrateLozenge200 ug/1Oral; TransmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl CitrateLozenge600 ug/1Oral; TransmucosalCima Labs Inc.1999-01-202016-10-31Us
Fentanyl CitrateLozenge800 ug/1Oral; TransmucosalPhysicians Total Care, Inc.2009-04-24Not applicableUs
Fentanyl CitrateLozenge1200 ug/1Oral; TransmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl CitrateLozenge400 ug/1Oral; TransmucosalPhysicians Total Care, Inc.2008-12-19Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousHospira, Inc.1985-01-12Not applicableUs
Fentanyl CitrateLozenge400 ug/1Oral; TransmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl CitrateLozenge800 ug/1Oral; TransmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl CitrateLozenge1200 ug/1Oral; TransmucosalPhysicians Total Care, Inc.2009-06-05Not applicableUs
Fentanyl CitrateLozenge1600 ug/1Oral; TransmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl CitrateLozenge200 ug/1Oral; TransmucosalPhysicians Total Care, Inc.2009-04-24Not applicableUs
Fentanyl CitrateLozenge600 ug/1Oral; TransmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl CitrateLozenge1200 ug/1Oral; TransmucosalCima Labs Inc.1999-01-202016-11-30Us
Fentanyl CitrateLozenge200 ug/1Oral; TransmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl CitrateLozenge600 ug/1Oral; TransmucosalPhysicians Total Care, Inc.2009-04-24Not applicableUs
Fentanyl CitrateLozenge800 ug/1Oral; TransmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl CitrateLozenge1600 ug/1Oral; TransmucosalCima Labs Inc.1999-01-202016-10-31Us
Fentanyl CitrateLozenge400 ug/1Oral; TransmucosalCima Labs Inc.1999-01-202016-10-31Us
Fentanyl CitrateInjection50 ug/mLIntramuscular; IntravenousAkorn, Inc.2012-03-22Not applicableUs
Fentanyl Citrate InjectionSolution50 mcgEpidural; Intramuscular; IntravenousHospira Healthcare Corporation1989-12-31Not applicableCanada
Fentanyl Citrate Injection SdzLiquid50 mcgEpidural; Intramuscular; IntravenousSandoz Canada Incorporated2013-02-21Not applicableCanada
Fentanyl Citrate Injection U.S.P.-liq IV Im EpdSolution50 mcgEpidural; Intramuscular; IntravenousHospira Healthcare Corporation1997-07-302011-08-05Canada
Fentanyl Citrate Injection USPSolution50 mcgEpidural; Intramuscular; IntravenousAlveda Pharmaceuticals Inc2016-04-18Not applicableCanada
Fentanyl Citrate Injection USPLiquid50 mcgEpidural; Intramuscular; IntravenousSandoz Canada Incorporated2000-02-10Not applicableCanada
Fentanyl Citrate Injection USP 50mcg/mlLiquid50 mcgEpidural; Intramuscular; IntravenousDavid Bull Laboratories (Canada) Inc.1993-12-311999-08-04Canada
Fentanyl PatchPatch100 mcgTransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl PatchPatch25 mcgTransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl PatchPatch50 mcgTransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl PatchPatch75 mcgTransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl PatchPatch12 mcgTransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl Transdermal System 100Patch, extended release100 mcgTransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentanyl Transdermal System 25Patch, extended release25 mcgTransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentanyl Transdermal System 50Patch, extended release50 mcgTransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentanyl Transdermal System 75Patch, extended release75 mcgTransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
FentoraTablet400 ug/1Buccal; SublingualCephalon, Inc.2006-09-25Not applicableUs
FentoraTablet, effervescent200 mcgBuccal; SublingualTeva Canada Limited2014-05-14Not applicableCanada
FentoraTablet600 ug/1Buccal; SublingualCephalon, Inc.2006-09-25Not applicableUs
FentoraTablet, effervescent400 mcgBuccal; SublingualTeva Canada Limited2014-05-14Not applicableCanada
FentoraTablet100 ug/1Buccal; SublingualCephalon, Inc.2006-09-25Not applicableUs
FentoraTablet, effervescent100 mcgBuccal; SublingualTeva Canada Limited2014-05-14Not applicableCanada
FentoraTablet800 ug/1Buccal; SublingualCephalon, Inc.2006-09-25Not applicableUs
FentoraTablet, effervescent600 mcgBuccal; SublingualTeva Canada Limited2014-05-14Not applicableCanada
FentoraTablet200 ug/1Buccal; SublingualCephalon, Inc.2006-09-25Not applicableUs
FentoraTablet, effervescent800 mcgBuccal; SublingualTeva Canada Limited2014-05-14Not applicableCanada
InstanylSolution100 mcgNasalTakeda Canada IncNot applicableNot applicableCanada
InstanylSolution50 mcgNasalTakeda Canada IncNot applicableNot applicableCanada
InstanylSolution200 mcgNasalTakeda Canada IncNot applicableNot applicableCanada
IonsysPatch40 ug/1TransdermalThe Medicines Company2015-06-01Not applicableUs
LazandaSpray100 ug/1NasalDepomed, Inc.2011-10-17Not applicableUs
LazandaSpray400 ug/1NasalArchimedes Pharma US Inc.2011-10-17Not applicableUs
LazandaSpray400 ug/1NasalDepomed, Inc.2011-10-17Not applicableUs
LazandaSpray300 ug/1NasalDepomed, Inc.2016-01-01Not applicableUs
LazandaSpray100 ug/1NasalArchimedes Pharma US Inc.2011-10-17Not applicableUs
Mylan-fentanyl Matrix PatchPatch75 mcgTransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix PatchPatch12 mcgTransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix PatchPatch100 mcgTransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix PatchPatch25 mcgTransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix PatchPatch50 mcgTransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
OnsolisFilm, soluble1200 mcgBuccalMeda Ab2011-08-222013-01-31Canada
OnsolisFilm, soluble200 mcgBuccalMeda Ab2011-08-222013-01-31Canada
OnsolisFilm, soluble400 mcgBuccalMeda Ab2011-08-222013-01-31Canada
OnsolisFilm, soluble600 mcgBuccalMeda Ab2011-08-222013-01-31Canada
OnsolisFilm, soluble800 mcgBuccalMeda Ab2011-08-222013-01-31Canada
Pat-fentanyl MatPatch50 mcgTransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl MatPatch75 mcgTransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl MatPatch12.0 mcgTransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl MatPatch100 mcgTransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl MatPatch25 mcgTransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
PMS-fentanyl MtxPatch75 mcgTransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl MtxPatch12 mcgTransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl MtxPatch100 mcgTransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl MtxPatch25 mcgTransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl MtxPatch50 mcgTransdermalPharmascience Inc2010-03-18Not applicableCanada
Ran-fentanyl Matrix PatchPatch100 mcgTransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix PatchPatch12 mcgTransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix PatchPatch25 mcgTransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix PatchPatch50 mcgTransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix PatchPatch75 mcgTransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Transdermal SystemPatch7.5 mgTransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Ran-fentanyl Transdermal SystemPatch10 mgTransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Ran-fentanyl Transdermal SystemPatch2.5 mgTransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Ran-fentanyl Transdermal SystemPatch5 mgTransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Sandoz Fentanyl PatchPatch37 mcgTransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl PatchPatch50 mcgTransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl PatchPatch12 mcgTransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl PatchPatch75 mcgTransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl PatchPatch25 mcgTransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl PatchPatch100 mcgTransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sublimaze Inj 50mcg/mlLiquid50 mcgEpidural; Intramuscular; IntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1987-12-311996-09-10Canada
SubsysSpray.1 mg/1SublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
SubsysSpray.8 mg/1SublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
SubsysSpray.2 mg/1SublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
SubsysSpray.6 mg/1SublingualInsys Therapeutics, Inc.2012-08-30Not applicableUs
SubsysSpray.4 mg/1SublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
SubsysSpray.8 mg/1SublingualInsys Therapeutics, Inc.2012-08-30Not applicableUs
SubsysSpray.6 mg/1SublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
Teva-fentanylPatch25 mcgTransdermalTeva Canada Limited2006-07-04Not applicableCanada
Teva-fentanylPatch12 mcgTransdermalTeva Canada Limited2008-06-27Not applicableCanada
Teva-fentanylPatch50 mcgTransdermalTeva Canada Limited2006-07-04Not applicableCanada
Teva-fentanylPatch75 mcgTransdermalTeva Canada Limited2006-07-04Not applicableCanada
Teva-fentanylPatch100 mcgTransdermalTeva Canada Limited2006-07-04Not applicableCanada
Transmucosal Fentanyl CitrateLozenge1200 1/1Oral; TransmucosalH.J. Harkins Company, Inc.2006-09-06Not applicableUs
Transmucosal Fentanyl CitrateLozenge600 ug/1Oral; TransmucosalH.J. Harkins Company, Inc.2006-09-06Not applicableUs
Transmucosal Fentanyl CitrateLozenge400 ug/1Oral; TransmucosalH.J. Harkins Company, Inc.2006-09-06Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fentanyl MatrixPatch75 mcgTransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl MatrixPatch12 mcgTransdermalApotex IncNot applicableNot applicableCanada
Apo-fentanyl MatrixPatch100 mcgTransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl MatrixPatch25 mcgTransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl MatrixPatch50 mcgTransdermalApotex Inc2009-05-13Not applicableCanada
FentanylPatch, extended release75 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalbryant ranch prepack2007-09-01Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalDispensing Solutions Inc.2006-11-06Not applicableUs
FentanylPatch87.5 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2015-02-24Not applicableUs
FentanylPatch75 ug/hTransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
FentanylPatch, extended release2.5 mg/72hTransdermalSTAT Rx USA LLC2007-08-20Not applicableUs
FentanylPatch2.55 mg/[USP'U]TransdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
FentanylPatch25 ug/hTransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalApotex Corp.2010-03-01Not applicableUs
FentanylPatch50 ug/hTransdermalCorium International, Inc.2007-08-20Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalTeva Pharmaceuticals USA Inc2008-12-222016-03-29Us
FentanylPatch100 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2013-01-09Not applicableUs
FentanylPatch87.5 ug/hTransdermalMylan Pharmaceuticals Inc.2015-02-24Not applicableUs
FentanylPatch1.28 mg/[USP'U]TransdermalPhysicians Total Care, Inc.2008-11-18Not applicableUs
FentanylPatch100 ug/hTransdermalSt. Marys Medical Park Pharmacy2011-01-26Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
FentanylPatch, extended release100 ug/72hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-12-09Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
FentanylPatch12 ug/hTransdermalMylan Pharmaceuticals Inc.2007-01-24Not applicableUs
FentanylPatch, extended release7.5 mg/72hTransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-09Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalbryant ranch prepack2013-04-04Not applicableUs
FentanylPatch100 ug/hTransdermalDAVA Pharmaceuticals, Inc.2010-11-012016-11-15Us
FentanylPatch, extended release5 mg/72hTransdermalSTAT Rx USA LLC2007-08-20Not applicableUs
FentanylPatch5.1 mg/[USP'U]TransdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalbryant ranch prepack2007-09-01Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
FentanylPatch, extended release25 ug/hTransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
FentanylPatch100 ug/hTransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalTeva Pharmaceuticals USA Inc2008-12-222016-03-29Us
FentanylPatch50 ug/hTransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch25 ug/hTransdermalDAVA Pharmaceuticals, Inc.2010-11-012016-11-15Us
FentanylPatch, extended release12 ug/hTransdermalApotex Corp.2016-01-22Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalApotex Corp.2010-03-01Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalbryant ranch prepack2010-03-01Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalDIRECT RX2015-01-01Not applicableUs
FentanylPatch25 ug/hTransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalH.J. Harkins Company, Inc.2010-03-01Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalbryant ranch prepack2013-04-04Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalDispensing Solutions Inc.2006-11-06Not applicableUs
FentanylPatch37.5 ug/hTransdermalMylan Pharmaceuticals Inc.2015-02-24Not applicableUs
FentanylPatch7.65 mg/[USP'U]TransdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
FentanylPatch25 ug/hTransdermalSt. Marys Medical Park Pharmacy2011-01-26Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalbryant ranch prepack2007-09-01Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
FentanylPatch, extended release25 ug/72hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-12-09Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalTeva Pharmaceuticals USA Inc2008-10-202016-03-29Us
FentanylPatch75 ug/hTransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalbryant ranch prepack2010-03-01Not applicableUs
FentanylPatch50 ug/hTransdermalDAVA Pharmaceuticals, Inc.2010-11-012016-11-15Us
FentanylPatch, extended release50 ug/hTransdermalApotex Corp.2010-03-01Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalDIRECT RX2015-01-01Not applicableUs
FentanylPatch25 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2005-01-28Not applicableUs
FentanylPatch50 ug/hTransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalH.J. Harkins Company, Inc.2010-03-01Not applicableUs
FentanylPatch, extended release50 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalbryant ranch prepack2013-04-04Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalDispensing Solutions Inc.2006-11-06Not applicableUs
FentanylPatch62.5 ug/hTransdermalMylan Pharmaceuticals Inc.2015-02-24Not applicableUs
FentanylPatch10.2 mg/[USP'U]TransdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
FentanylPatch50 ug/hTransdermalSt. Marys Medical Park Pharmacy2011-01-26Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalbryant ranch prepack2007-09-01Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
FentanylPatch, extended release50 ug/72hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-12-09Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
FentanylPatch, extended release100 ug/hTransdermalTeva Pharmaceuticals USA Inc2008-10-202016-03-29Us
FentanylPatch100 ug/hTransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalApotex Corp.2013-04-04Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalbryant ranch prepack2010-03-01Not applicableUs
FentanylPatch75 ug/hTransdermalDAVA Pharmaceuticals, Inc.2010-11-012016-11-15Us
FentanylPatch12 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2013-01-09Not applicableUs
FentanylPatch, extended release75 ug/hTransdermalApotex Corp.2010-03-01Not applicableUs
FentanylPatch, extended release25 ug/hTransdermalbryant ranch prepack2010-03-01Not applicableUs
Fentanyl - NovaplusPatch, extended release75 ug/hTransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl - NovaplusPatch, extended release100 ug/hTransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl - NovaplusPatch, extended release25 ug/hTransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl - NovaplusPatch, extended release50 ug/hTransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl BuccalTablet600 ug/1Buccal; Oral; TransmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl BuccalTablet800 ug/1Buccal; Oral; TransmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl BuccalTablet100 ug/1Buccal; Oral; TransmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl BuccalTablet200 ug/1Buccal; Oral; TransmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl BuccalTablet400 ug/1Buccal; Oral; TransmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateLozenge1600 ug/1TransmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl CitrateLozenge600 ug/1Oral; TransmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateLozenge600 ug/1TransmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateLozenge800 ug/1Oral; TransmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl CitrateLozenge800 ug/1Oral; TransmucosalLake Erie Medical DBA Quality Care Products LLC2011-10-17Not applicableUs
Fentanyl CitrateLozenge800 ug/1TransmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl CitrateLozenge200 ug/1Oral; TransmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateLozenge200 ug/1TransmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl CitrateLozenge1200 ug/1Oral; TransmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl CitrateLozenge1200 ug/1TransmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateLozenge400 ug/1Oral; TransmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl CitrateInjection50 ug/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl CitrateLozenge400 ug/1TransmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl CitrateInjection, solution50 ug/mLIntramuscular; IntravenousHospira, Inc.1991-09-24Not applicableUs
Fentanyl CitrateLozenge1600 ug/1Oral; TransmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl SystemPatch12.5 ug/1TransdermalAlvogen, Inc.2016-11-04Not applicableUs
Fentanyl SystemPatch100 ug/1TransdermalAlvogen, Inc.2016-11-04Not applicableUs
Fentanyl SystemPatch25 ug/1TransdermalAlvogen, Inc.2016-11-04Not applicableUs
Fentanyl SystemPatch50 ug/1TransdermalAlvogen, Inc.2016-11-04Not applicableUs
Fentanyl SystemPatch75 ug/1TransdermalAlvogen, Inc.2016-11-04Not applicableUs
Fentanyl Transdermal SystemPatch, extended release50 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release50 ug/hTransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release50 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release100 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release25 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release75 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release75 ug/hTransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release100 ug/hTransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release75 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release50 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release12.5 ug/hTransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release100 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release25 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release25 ug/hTransdermalRebel Distributors Corp2011-02-09Not applicableUs
Fentanyl Transdermal SystemPatch, extended release50 ug/hTransdermalRebel Distributors Corp.2011-02-09Not applicableUs
Fentanyl Transdermal SystemPatch, extended release75 ug/hTransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release25 ug/hTransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal SystemPatch, extended release100 ug/hTransdermalbryant ranch prepack2011-06-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fentanyl CitrateInjection, solution10 ug/mLIntravenousCantrell Drug Company2011-07-26Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntravenousCantrell Drug Company2013-03-14Not applicableUs
Fentanyl CitrateInjection, solution20 ug/mLIntravenousCantrell Drug Company2013-01-30Not applicableUs
Fentanyl CitrateInjection, solution5 ug/mLIntravenousCantrell Drug Company2013-11-22Not applicableUs
Fentanyl CitrateInjection, solution25 ug/mLIntravenousCantrell Drug Company2012-10-19Not applicableUs
Fentanyl CitrateInjection, solution50 ug/mLIntravenousCantrell Drug Company2011-10-20Not applicableUs
IonsysPatch40 μg/doseTransdermalJanssen Cilag International Nv2006-01-24Not applicableEu
International Brands
NameCompany
DurogesicJanssen
FentanestPfizer
NasalfentArchimedes
RapinylGedeon Richter
Brand mixtures
NameLabellerIngredients
Fentanyl Citrate, Bupivacaine HClCantrell Drug Company
Innovar InjJanssen Pharmaceutica, Division Of Janssen Ortho Inc.
Salts
Name/CASStructureProperties
Fentanyl citrate
990-73-8
Thumb
  • InChI Key: IVLVTNPOHDFFCJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 528.247166138
  • Average Mass: 528.594
DBSALT000301
Fentanyl hydrochloride
1443-54-5
Thumb
  • InChI Key: LHCBOXPPRUIAQT-UHFFFAOYSA-N
  • Monoisotopic Mass: 372.1968413
  • Average Mass: 372.94
DBSALT001226
Categories
UNIIUF599785JZ
CAS number437-38-7
WeightAverage: 336.4705
Monoisotopic: 336.220163528
Chemical FormulaC22H28N2O
InChI KeyPJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
IUPAC Name
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
Structured Indications
PharmacodynamicsFentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
Mechanism of actionOpiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hypopolarization and reduced neuronal excitability.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
Kappa-type opioid receptorProteinunknown
agonist
HumanP41145 details
Related Articles
AbsorptionBioavailability is 92% following transdermal administration and 50% following buccal administration.
Volume of distribution
  • 3 to 8 L/kg [Surgical Patients]
  • 0.8 to 8 [Hepatically Impaired Patients]
Protein binding80-85%
Metabolism

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system.

SubstrateEnzymesProduct
Fentanyl
norfentanylDetails
Route of eliminationFentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.
Half life7 hours (range 3-12)
Clearance
  • 27 – 75 L/h [Surgical Patients receving IV administration]
  • 3 – 80 L/h [Hepatically Impaired Patients receving IV administration]
  • 30 – 78 L/h [Renally Impaired Patients receving IV administration]
ToxicityFentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fentanyl Action PathwayDrug actionSMP00415
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Fentanyl.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEFentanyl may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fentanyl.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fentanyl.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Fentanyl.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fentanyl.Approved
adipiplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fentanyl.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fentanyl.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fentanyl.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Fentanyl.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fentanyl.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fentanyl.Approved, Illicit, Investigational
AlprenololFentanyl may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alvimopan.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fentanyl.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fentanyl.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fentanyl.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fentanyl.Approved
Aop200704Fentanyl may increase the bradycardic activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fentanyl.Approved
AprepitantThe serum concentration of Fentanyl can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.Approved, Investigational
ArotinololFentanyl may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fentanyl.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Asenapine.Approved
AtazanavirThe serum concentration of Fentanyl can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fentanyl.Approved
AtomoxetineThe serum concentration of Fentanyl can be increased when it is combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fentanyl.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Fentanyl.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fentanyl.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azaperone.Vet Approved
AzelastineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.Illicit
BefunololFentanyl may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Fentanyl.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bendroflumethiazide.Approved
BenmoxinFentanyl may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fentanyl.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fentanyl.Approved, Vet Approved
BetaxololFentanyl may increase the bradycardic activities of Betaxolol.Approved
BevantololFentanyl may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe serum concentration of Fentanyl can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Fentanyl.Approved
BisoprololFentanyl may increase the bradycardic activities of Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Fentanyl.Investigational
BoceprevirThe serum concentration of Fentanyl can be increased when it is combined with Boceprevir.Approved
BopindololFentanyl may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe serum concentration of Fentanyl can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fentanyl can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fentanyl.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fentanyl.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
BromazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brotizolam.Approved, Withdrawn
BucindololFentanyl may increase the bradycardic activities of Bucindolol.Investigational
BufuralolFentanyl may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fentanyl.Approved, Investigational
BupranololFentanyl may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fentanyl.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fentanyl.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Fentanyl.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fentanyl.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fentanyl.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Fentanyl.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fentanyl.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fentanyl.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Canrenone.Investigational
CarbamazepineThe serum concentration of Fentanyl can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fentanyl.Approved
CariprazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carisoprodol.Approved
CaroxazoneFentanyl may increase the serotonergic activities of Caroxazone.Withdrawn
CarteololFentanyl may increase the bradycardic activities of Carteolol.Approved
CarvedilolFentanyl may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololFentanyl may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Fentanyl can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fentanyl.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fentanyl.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Fentanyl.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Fentanyl.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Fentanyl.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cicletanine.Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fentanyl.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fentanyl.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fentanyl.Approved, Investigational
CirazolineThe serum concentration of Fentanyl can be decreased when it is combined with Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fentanyl.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl.Approved
ClarithromycinThe serum concentration of Fentanyl can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Fentanyl can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fentanyl.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fentanyl.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Fentanyl.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Fentanyl.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fentanyl.Approved, Illicit
ClotrimazoleThe serum concentration of Fentanyl can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fentanyl.Approved
CobicistatThe serum concentration of Fentanyl can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fentanyl.Approved
CocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fentanyl.Approved
ConivaptanThe serum concentration of Fentanyl can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fentanyl.Approved
CrizotinibThe serum concentration of Fentanyl can be increased when it is combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fentanyl.Approved
CyclosporineThe serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fentanyl.Approved
DabrafenibThe serum concentration of Fentanyl can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fentanyl.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Fentanyl.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fentanyl.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fentanyl.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl.Approved, Investigational
DarunavirThe serum concentration of Fentanyl can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Fentanyl can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Fentanyl can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fentanyl.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fentanyl.Approved
DeferasiroxThe serum concentration of Fentanyl can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Fentanyl can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Fentanyl can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Fentanyl.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fentanyl.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fentanyl.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fentanyl.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fentanyl.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Fentanyl.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fentanyl.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fentanyl.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fentanyl.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Fentanyl can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fentanyl.Illicit
DiltiazemThe serum concentration of Fentanyl can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fentanyl.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fentanyl.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Fentanyl.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fentanyl.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fentanyl.Approved, Investigational
DoxycyclineThe serum concentration of Fentanyl can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fentanyl is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit
DronedaroneThe serum concentration of Fentanyl can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fentanyl.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fentanyl.Approved
EcgonineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Fentanyl is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fentanyl.Approved
EfavirenzThe serum concentration of Fentanyl can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fentanyl.Approved, Investigational
EluxadolineFentanyl may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fentanyl.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Fentanyl.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Eplerenone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Fentanyl can be decreased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fentanyl.Approved, Investigational
ErythromycinThe serum concentration of Fentanyl can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Fentanyl is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Fentanyl can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololFentanyl may increase the bradycardic activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fentanyl.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Fentanyl.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Fentanyl.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fentanyl.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.Approved
EthanolFentanyl may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fentanyl.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fentanyl.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Fentanyl.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fentanyl.Approved
EtoperidoneFentanyl may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fentanyl.Approved
EtorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Fentanyl can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fentanyl.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fentanyl.Approved
EzogabineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fencamfamine.Approved, Illicit, Withdrawn
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Fentanyl.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fentanyl.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fentanyl.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flibanserin.Approved
FluconazoleThe serum concentration of Fentanyl can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fentanyl.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fentanyl.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fentanyl.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fentanyl.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Fentanyl can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fentanyl can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fentanyl can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fentanyl can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Frovatriptan.Approved, Investigational
FurazolidoneFentanyl may increase the serotonergic activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fentanyl can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fentanyl is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fentanyl.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fentanyl.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fentanyl.Approved
GepironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Fentanyl.Approved, Investigational, Vet Approved
GranisetronGranisetron may increase the serotonergic activities of Fentanyl.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fentanyl.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fentanyl.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fentanyl.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fentanyl.Approved
HalothaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Fentanyl.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Fentanyl.Approved
HydracarbazineFentanyl may increase the serotonergic activities of Hydracarbazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneFentanyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fentanyl.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Fentanyl.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fentanyl.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fentanyl.Approved
IdelalisibThe serum concentration of Fentanyl can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iloperidone.Approved
ImatinibThe serum concentration of Fentanyl can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fentanyl.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Fentanyl.Approved
IndalpineFentanyl may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.Approved
IndenololFentanyl may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Fentanyl can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fentanyl.Approved, Investigational
Ioflupane I-123Fentanyl may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.Approved
IproclozideFentanyl may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidFentanyl may increase the serotonergic activities of Iproniazid.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fentanyl.Approved, Investigational
IsavuconazoniumThe serum concentration of Fentanyl can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidFentanyl may increase the serotonergic activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fentanyl.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isosorbide.Approved
IsradipineThe serum concentration of Fentanyl can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Fentanyl can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fentanyl can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fentanyl.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fentanyl.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Fentanyl can be increased when it is combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Fentanyl is combined with KW-3902.Investigational
LabetalolFentanyl may increase the bradycardic activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fentanyl.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fentanyl.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fentanyl.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fentanyl.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fentanyl.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Fentanyl.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fentanyl.Approved, Investigational
LevobunololFentanyl may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fentanyl.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fentanyl.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fentanyl.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fentanyl.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Fentanyl.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fentanyl.Approved
LopinavirThe serum concentration of Fentanyl can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fentanyl.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Fentanyl.Approved
LovastatinThe serum concentration of Fentanyl can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fentanyl.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Fentanyl is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Fentanyl can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fentanyl can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Maprotiline.Approved
MebanazineFentanyl may increase the serotonergic activities of Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.Approved
MeclizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Fentanyl is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Fentanyl.Investigational
MephentermineThe serum concentration of Fentanyl can be decreased when it is combined with Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mesoridazine.Approved
MetaraminolThe serum concentration of Fentanyl can be decreased when it is combined with Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fentanyl.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fentanyl.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fentanyl.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fentanyl.Approved
MethotrimeprazineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineThe serum concentration of Fentanyl can be decreased when it is combined with Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.Approved
Methylene blueFentanyl may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl.Approved, Vet Approved
MetipranololFentanyl may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Fentanyl.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fentanyl.Approved, Investigational
MetyrosineFentanyl may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fentanyl.Approved, Illicit
MidodrineThe serum concentration of Fentanyl can be decreased when it is combined with Midodrine.Approved
MifepristoneThe serum concentration of Fentanyl can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Fentanyl is combined with Milnacipran.Approved
MinaprineFentanyl may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Fentanyl.Approved
MirtazapineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Fentanyl can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fentanyl.Approved, Investigational
MMDAMMDA may increase the analgesic activities of Fentanyl.Experimental, Illicit
MoclobemideFentanyl may increase the serotonergic activities of Moclobemide.Approved
ModafinilThe serum concentration of Fentanyl can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Fentanyl.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Fentanyl.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fentanyl.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Fentanyl.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Fentanyl.Approved
NafcillinThe serum concentration of Fentanyl can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Fentanyl.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fentanyl.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fentanyl.Approved, Vet Approved
NaltrexoneThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Naratriptan.Approved, Investigational
NefazodoneThe serum concentration of Fentanyl can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fentanyl can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fentanyl can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Fentanyl can be increased when it is combined with Nevirapine.Approved
NialamideFentanyl may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fentanyl.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fentanyl.Approved
NilotinibThe serum concentration of Fentanyl can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fentanyl.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fentanyl.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fentanyl.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Fentanyl.Investigational
OctamoxinFentanyl may increase the serotonergic activities of Octamoxin.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Fentanyl.Approved, Investigational
OlaparibThe serum concentration of Fentanyl can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Fentanyl can be increased when it is combined with Ombitasvir.Approved
OndansetronOndansetron may increase the serotonergic activities of Fentanyl.Approved
OpiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Opium.Approved, Illicit
OrphenadrineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Fentanyl can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fentanyl.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fentanyl.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fentanyl.Approved, Vet Approved
PalbociclibThe serum concentration of Fentanyl can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Fentanyl.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fentanyl.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Fentanyl.Approved, Investigational
ParaldehydeFentanyl may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineFentanyl may increase the serotonergic activities of Pargyline.Approved
ParitaprevirThe serum concentration of Fentanyl can be increased when it is combined with Paritaprevir.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fentanyl.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fentanyl.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.Approved
PenbutololFentanyl may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentazocinePentazocine may decrease the analgesic activities of Fentanyl.Approved, Vet Approved
PentobarbitalThe serum concentration of Fentanyl can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fentanyl.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
PerazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fentanyl.Approved
PhenelzineFentanyl may increase the serotonergic activities of Phenelzine.Approved
PheniprazineFentanyl may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe serum concentration of Fentanyl can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Phenoxyethanol.Approved
PhenoxypropazineFentanyl may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Fentanyl.Approved, Illicit
PhenylephrineThe serum concentration of Fentanyl can be decreased when it is combined with Phenylephrine.Approved
PhenytoinThe serum concentration of Fentanyl can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pimozide.Approved
PindololFentanyl may increase the bradycardic activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fentanyl.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.Approved
PiretanideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piritramide.Investigational
PirlindoleFentanyl may increase the serotonergic activities of Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fentanyl.Approved
PivhydrazineFentanyl may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fentanyl.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fentanyl.Approved
PosaconazoleThe serum concentration of Fentanyl can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.Approved, Vet Approved
PractololFentanyl may increase the bradycardic activities of Practolol.Approved
PramipexoleFentanyl may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fentanyl.Approved
PrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fentanyl.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fentanyl.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fentanyl.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fentanyl.Approved
PrimidoneThe serum concentration of Fentanyl can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fentanyl.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fentanyl.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fentanyl.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Fentanyl.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fentanyl.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fentanyl.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fentanyl.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propericiazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Fentanyl.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Fentanyl.Investigational
PropofolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fentanyl.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fentanyl.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fentanyl.Approved
PSD502The risk or severity of adverse effects can be increased when Fentanyl is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Fentanyl.Approved
QuazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Fentanyl.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fentanyl.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Fentanyl.Approved
RacloprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ramelteon.Approved, Investigational
RamosetronFentanyl may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fentanyl.Approved
RanolazineThe serum concentration of Fentanyl can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineFentanyl may increase the serotonergic activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fentanyl.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Fentanyl.Approved
RifabutinThe serum concentration of Fentanyl can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fentanyl can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fentanyl can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fentanyl.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Fentanyl.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Fentanyl.Investigational
RitonavirThe serum concentration of Fentanyl can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fentanyl.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rizatriptan.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rolofylline.Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fentanyl.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Romifidine.Vet Approved
RopiniroleFentanyl may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fentanyl.Approved
RotigotineFentanyl may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fentanyl.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Fentanyl is combined with S-Ethylisothiourea.Experimental
SafrazineFentanyl may increase the serotonergic activities of Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Fentanyl is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fentanyl.Approved, Vet Approved
SaquinavirThe serum concentration of Fentanyl can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Fentanyl.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fentanyl.Approved, Vet Approved
SelegilineFentanyl may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fentanyl.Approved
SertindoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Fentanyl can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fentanyl.Approved
SiltuximabThe serum concentration of Fentanyl can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fentanyl can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fentanyl.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fentanyl.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fentanyl.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Fentanyl.Approved, Investigational
SotalolFentanyl may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fentanyl.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fentanyl.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Fentanyl can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Fentanyl can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Fentanyl.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.Approved, Investigational
SulfisoxazoleThe serum concentration of Fentanyl can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fentanyl.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fentanyl.Approved, Investigational
SuvorexantFentanyl may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fentanyl.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fentanyl.Approved
TandospironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fentanyl.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fentanyl.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fentanyl.Approved
TelaprevirThe serum concentration of Fentanyl can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Fentanyl can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fentanyl.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fentanyl.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrodotoxin.Investigational
ThalidomideFentanyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Fentanyl.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fentanyl.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fentanyl.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fentanyl.Approved
TiclopidineThe serum concentration of Fentanyl can be increased when it is combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Fentanyl.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Fentanyl.Approved
TizanidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Fentanyl can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolcapone.Approved, Withdrawn
ToloxatoneFentanyl may increase the serotonergic activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fentanyl.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fentanyl.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Fentanyl.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fentanyl.Approved, Investigational
Trans-2-PhenylcyclopropylamineFentanyl may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineFentanyl may increase the serotonergic activities of Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fentanyl.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fentanyl.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fentanyl.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fentanyl.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fentanyl.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fentanyl.Approved
TropisetronTropisetron may increase the serotonergic activities of Fentanyl.Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Fentanyl.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fentanyl.Approved
Uc1010The risk or severity of adverse effects can be increased when Fentanyl is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ularitide.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fentanyl.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fentanyl.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fentanyl.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fentanyl.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Fentanyl.Approved
VenlafaxineThe serum concentration of Fentanyl can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Fentanyl can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fentanyl.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fentanyl.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fentanyl.Approved
VoriconazoleThe serum concentration of Fentanyl can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fentanyl.Approved
ZimelidineFentanyl may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Fentanyl can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fentanyl.Approved, Investigational
ZolpidemFentanyl may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
References
Synthesis Reference

Mark Rubino, “Process of making fentanyl intermediates.” U.S. Patent US20060100438, issued May 11, 2006.

US20060100438
General References
  1. Van Bever WF, Niemegeers CJ, Janssen PA: Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. J Med Chem. 1974 Oct;17(10):1047-51. [PubMed:4420811 ]
  2. Messina J, Darwish M, Fine PG: Fentanyl buccal tablet. Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. [PubMed:18301803 ]
  3. Taylor DR: Fentanyl buccal tablet: rapid relief from breakthrough pain. Expert Opin Pharmacother. 2007 Dec;8(17):3043-51. [PubMed:18001263 ]
  4. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Apr;29(4):588-601. [PubMed:17617282 ]
External Links
ATC CodesN01AH51N01AH01N02AB03
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (507 KB)
MSDSDownload (75.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9766
Blood Brain Barrier+0.9901
Caco-2 permeable+0.6459
P-glycoprotein substrateSubstrate0.6082
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.8371
Renal organic cation transporterInhibitor0.5824
CYP450 2C9 substrateNon-substrate0.7879
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5856
CYP450 1A2 substrateNon-inhibitor0.7715
CYP450 2C9 inhibitorNon-inhibitor0.873
CYP450 2D6 inhibitorNon-inhibitor0.6327
CYP450 2C19 inhibitorNon-inhibitor0.5724
CYP450 3A4 inhibitorNon-inhibitor0.8218
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7346
Ames testNon AMES toxic0.8417
CarcinogenicityNon-carcinogens0.8536
BiodegradationNot ready biodegradable0.8554
Rat acute toxicity3.9836 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.796
hERG inhibition (predictor II)Inhibitor0.6791
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis southatlantic llc
  • Lavipharm laboratories inc
  • Mylan technologies inc
  • Noven pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Meda pharmaceuticals inc
  • Abbott laboratories hosp products div
  • Hospira inc
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Akorn inc
  • Cephalon inc
  • Barr laboratories inc
  • Mallinckrodt inc
  • Incline therapeutics inc
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
TabletSublingual100 mcg
TabletSublingual100 ug/1
TabletSublingual200 mcg
TabletSublingual200 ug/1
TabletSublingual300 ug/1
TabletSublingual300 mcg
TabletSublingual400 ug/1
TabletSublingual400 mcg
TabletSublingual600 mcg
TabletSublingual600 ug/1
TabletSublingual800 mcg
TabletSublingual800 ug/1
Tablet, orally disintegratingSublingual100 ug/1
Tablet, orally disintegratingSublingual200 ug/1
Tablet, orally disintegratingSublingual300 ug/1
Tablet, orally disintegratingSublingual400 ug/1
Tablet, orally disintegratingSublingual600 ug/1
Tablet, orally disintegratingSublingual800 ug/1
TabletBuccal100 micrograms
TabletBuccal200 micrograms
TabletBuccal400 micrograms
TabletBuccal600 micrograms
TabletBuccal800 micrograms
PatchTransdermal1.28 mg/[USP'U]
PatchTransdermal10.2 mg/[USP'U]
PatchTransdermal100 ug/h
PatchTransdermal12 ug/h
PatchTransdermal12 ug/1
PatchTransdermal12.5 ug/h
PatchTransdermal2.55 mg/[USP'U]
PatchTransdermal25 ug/h
PatchTransdermal37.5 ug/h
PatchTransdermal5.1 mg/[USP'U]
PatchTransdermal50 ug/h
PatchTransdermal62.5 ug/h
PatchTransdermal7.65 mg/[USP'U]
PatchTransdermal75 ug/h
PatchTransdermal87.5 ug/h
Patch, extended releaseTransdermal100 ug/h
Patch, extended releaseTransdermal100 ug/72h
Patch, extended releaseTransdermal12 ug/h
Patch, extended releaseTransdermal2.5 mg/72h
Patch, extended releaseTransdermal25 ug/h
Patch, extended releaseTransdermal25 ug/72h
Patch, extended releaseTransdermal5 mg/72h
Patch, extended releaseTransdermal50 ug/h
Patch, extended releaseTransdermal50 ug/72h
Patch, extended releaseTransdermal7.5 mg/72h
Patch, extended releaseTransdermal75 ug/h
TabletBuccal; Oral; Transmucosal100 ug/1
TabletBuccal; Oral; Transmucosal200 ug/1
TabletBuccal; Oral; Transmucosal400 ug/1
TabletBuccal; Oral; Transmucosal600 ug/1
TabletBuccal; Oral; Transmucosal800 ug/1
InjectionIntramuscular; Intravenous50 ug/mL
InjectionIntravenous50 ug/mL
Injection, solutionIntramuscular; Intravenous50 ug/mL
Injection, solutionIntravenous10 ug/mL
Injection, solutionIntravenous20 ug/mL
Injection, solutionIntravenous25 ug/mL
Injection, solutionIntravenous5 ug/mL
Injection, solutionIntravenous50 ug/mL
LozengeOral; Transmucosal1200 ug/1
LozengeOral; Transmucosal1600 ug/1
LozengeOral; Transmucosal200 ug/1
LozengeOral; Transmucosal400 ug/1
LozengeOral; Transmucosal600 ug/1
LozengeOral; Transmucosal800 ug/1
LozengeTransmucosal1200 ug/1
LozengeTransmucosal1600 ug/1
LozengeTransmucosal200 ug/1
LozengeTransmucosal400 ug/1
LozengeTransmucosal600 ug/1
LozengeTransmucosal800 ug/1
SolutionEpidural; Intramuscular; Intravenous50 mcg
LiquidEpidural; Intramuscular; Intravenous50 mcg
Injection, solutionEpidural
PatchTransdermal100 ug/1
PatchTransdermal12.5 ug/1
PatchTransdermal25 ug/1
PatchTransdermal50 ug/1
PatchTransdermal75 ug/1
Patch, extended releaseTransdermal12.5 ug/h
Patch, extended releaseTransdermal100 mcg
Patch, extended releaseTransdermal25 mcg
Patch, extended releaseTransdermal50 mcg
Patch, extended releaseTransdermal75 mcg
TabletBuccal; Sublingual100 ug/1
TabletBuccal; Sublingual200 ug/1
TabletBuccal; Sublingual400 ug/1
TabletBuccal; Sublingual600 ug/1
TabletBuccal; Sublingual800 ug/1
Tablet, effervescentBuccal; Sublingual100 mcg
Tablet, effervescentBuccal; Sublingual200 mcg
Tablet, effervescentBuccal; Sublingual400 mcg
Tablet, effervescentBuccal; Sublingual600 mcg
Tablet, effervescentBuccal; Sublingual800 mcg
LiquidIntramuscular; Intravenous
SolutionNasal100 mcg
SolutionNasal200 mcg
SolutionNasal50 mcg
PatchTransdermal40 ug/1
PatchTransdermal40 μg/dose
SprayNasal100 ug/1
SprayNasal300 ug/1
SprayNasal400 ug/1
Film, solubleBuccal1200 mcg
Film, solubleBuccal200 mcg
Film, solubleBuccal400 mcg
Film, solubleBuccal600 mcg
Film, solubleBuccal800 mcg
PatchTransdermal12.0 mcg
PatchTransdermal10 mg
PatchTransdermal2.5 mg
PatchTransdermal5 mg
PatchTransdermal7.5 mg
PatchTransdermal37 mcg
SpraySublingual.1 mg/1
SpraySublingual.2 mg/1
SpraySublingual.4 mg/1
SpraySublingual.6 mg/1
SpraySublingual.8 mg/1
PatchTransdermal100 mcg
PatchTransdermal12 mcg
PatchTransdermal25 mcg
PatchTransdermal50 mcg
PatchTransdermal75 mcg
LozengeOral; Transmucosal1200 1/1
Prices
Unit descriptionCostUnit
Fentanyl base powder1498.18USD g
Fentanyl citrate powder1062.5USD g
Duragesic-100 5 100 mcg/hr Patches Box411.59USD box
Duragesic-75 5 75 mcg/hr Patches Box318.93USD box
Fentanyl 5 100 mcg/hr Patches Box210.0USD box
Duragesic-50 5 50 mcg/hr Patches Box205.78USD box
Actiq 1600 mcg lozenge150.29USD lozenge
Fentanyl 5 50 mcg/hr Patches Box129.99USD box
Actiq 1200 mcg lozenge121.82USD lozenge
Actiq 1600 mcg Lollipop119.42USD lollipop
Duragesic-25 5 25 mcg/hr Patches Box114.42USD box
Duragesic-12 5 12 mcg/hr Patches Box95.99USD box
Actiq 800 mcg lozenge93.76USD lozenge
Actiq 1200 mcg Lollipop85.7USD lollipop
Duragesic 100 mcg/hr patch81.36USD patch
Actiq 600 mcg lozenge79.16USD lozenge
Actiq 800 mcg Lollipop75.98USD lollipop
Fentanyl 5 12 (12.5)mcg/hr Patches Box67.99USD box
Fentanyl 5 25 mcg/hr Patches Box66.66USD box
Actiq 600 mcg Lollipop65.13USD lollipop
Actiq 400 mcg lozenge64.62USD lozenge
Fentanyl 100 mcg/hr patch61.69USD patch
Duragesic 75 mcg/hr patch61.3USD patch
Fentora 800 mcg buccal tablet54.77USD tablet
Actiq 400 mcg Lollipop53.75USD lollipop
Actiq 200 mcg lozenge51.05USD lozenge
Fentora 600 mcg buccal tablet47.37USD tablet
Fentanyl 75 mcg/hr patch46.48USD patch
Actiq 200 mcg Lollipop42.14USD lollipop
Duragesic 50 mcg/hr patch40.19USD patch
FentaNYL Citrate 1600 mcg Lollipop38.53USD lollipop
Fentora 400 mcg buccal tablet34.24USD tablet
Fentanyl 50 mcg/hr patch30.47USD patch
FentaNYL Citrate 1200 mcg Lollipop30.0USD lollipop
Fentora 300 mcg buccal tablet28.84USD tablet
Fentora 200 mcg buccal tablet23.57USD tablet
Duragesic 25 mcg/hr patch21.98USD patch
FentaNYL Citrate 400 mcg Lollipop20.0USD lollipop
Fentora 100 mcg buccal tablet18.64USD tablet
Duragesic 12 mcg/hr patch18.21USD patch
Fentanyl 25 mcg/hr patch16.67USD patch
Fentanyl 12 mcg/hr patch13.8USD patch
Fentanyl 0.05 mg/ml vial1.96USD ml
Fentanyl cit 1500 mcg/30 ml1.44USD ml
Fentanyl-ns 50 mcg/ml syringe1.0USD ml
Fentanyl-ns 300 mcg/30 ml syr0.99USD ml
Fentanyl-ns 20 mcg/ml syringe0.72USD ml
Fentanyl-ns 10 mcg/ml syringe0.64USD ml
Fentanyl cit 2750 mcg/55 ml0.35USD ml
Fentanyl-ns 500 mcg/50 ml syr0.31USD ml
Sublimaze 0.05 mg/ml ampul0.23USD ml
Fentanyl 0.05 mg/ml ampul0.21USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5697896 No1996-12-162016-12-16Us
US5843014 No1995-12-012015-12-01Us
US6159498 No1996-10-182016-10-18Us
US6169920 No1998-01-022018-01-02Us
US6181963 No1999-11-022019-11-02Us
US6195582 No1999-01-282019-01-28Us
US6200604 No1999-03-262019-03-26Us
US6317629 No1995-06-022012-06-02Us
US6432440 No1998-04-202018-04-20Us
US6759059 No1999-09-242019-09-24Us
US6761910 No1999-09-242019-09-24Us
US6881208 No2002-04-192022-04-19Us
US6974590 No1999-03-262019-03-26Us
US6975902 No2004-04-012024-04-01Us
US7579019 No2000-01-222020-01-22Us
US7862832 No2008-06-152028-06-15Us
US7862833 No2008-06-152028-06-15Us
US7910132 No1999-09-242019-09-24Us
US8092832 No2004-12-302024-12-30Us
US8119158 No2004-12-302024-12-30Us
US8216604 No2004-10-032024-10-03Us
US8301238 No2011-09-302031-09-30Us
US8428708 No2012-05-212032-05-21Us
US8428709 No2012-06-112032-06-11Us
US8486972 No2010-04-272030-04-27Us
US8486973 No2010-04-272030-04-27Us
US8728441 No1999-03-262019-03-26Us
US8753611 No1999-03-262019-03-26Us
US8765100 No1999-03-262019-03-26Us
US8781571 No2012-03-312032-03-31Us
US8835459 No2007-01-252027-01-25Us
US8835460 No2007-01-252027-01-25Us
US8889176 No2004-01-162024-01-16Us
US9078814 No2004-01-082024-01-08Us
US9095706 No2013-02-032033-02-03Us
US9241935 No2007-01-252027-01-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point83-84 US. Patent 3,141,823.
water solubility200 mg/L (at 25 °C)ROY,SD & FLYNN,GL (1988)
logP4.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.024 mg/mLALOGPS
logP4.12ALOGPS
logP3.82ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.48 m3·mol-1ChemAxon
Polarizability40.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9850000000-7ce3a6f35f5dee98185fView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassFentanyls
Direct ParentFentanyls
Alternative Parents
Substituents
  • Fentanyl
  • Anilide
  • Phenethylamine
  • Aralkylamine
  • 4-aminopiperidine
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. [PubMed:15589524 ]
  2. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [PubMed:16114980 ]
  3. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [PubMed:16332149 ]
  4. Dosen-Micovic L, Ivanovic M, Micovic V: Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006 May 1;14(9):2887-95. Epub 2006 Jan 11. [PubMed:16376082 ]
  5. Dardonville C, Fernandez-Fernandez C, Gibbons SL, Ryan GJ, Jagerovic N, Gabilondo AM, Meana JJ, Callado LF: Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem. 2006 Oct 1;14(19):6570-80. Epub 2006 Jun 23. [PubMed:16797997 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [PubMed:19403616 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [PubMed:15665994 ]
  2. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [PubMed:15828941 ]
  3. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [PubMed:15868528 ]
  4. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [PubMed:16372825 ]
  5. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [PubMed:16861092 ]
  6. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [PubMed:19403616 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [PubMed:18325678 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20. [PubMed:11964599 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:52